ABBV Showing Recent Insider Activity
Recent activity shows that AbbVie, ABBV the Insider Confidence level is trending n/a due to Corporate Insiders of ABBV n/a n/a worth of shares in the last 3 months.Before you dig into this report it is important to remember that "Insider Buying" is the purchase of shares in a corporation by a director, officer, or executive within the company. Insider buying is not the same as insider trading, which refers to corporate insiders making illegal stock purchases based on non-public information.
"Insider Buying" is not a crime when the buying is based on public information.
Additionally, since insiders have unique insights into their own companies, they often gobble up shares when they believe the stock is undervalued or dump stock when it’s time to sell. That's why people pay attention to insider buying.
- Stewart Jeffrey Ryan - EVP & CCO, $4,408,248 worth of shares on 1 month ago
- Strom Carrie C - SVP & Pres Global Allerg Aesth, $35,762 worth of shares on 1 day ago
- Durkin Brian L - VP, Controller, $2,794,200 worth of shares on 1 month ago
- Strom Carrie C - SVP & Pres Global Allerg Aesth, $120,900 worth of shares on 2 months ago
In addition, TradingView issued a Sell rating for ABBV over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook.
AbbVie, ABBV
Summary: AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
- Last Price: $152.6
- Price Change: $1.64, 1.0864%
- Yearly Gain: 37.13%
- Market Cap: $269.66B
- P/E Ratio: 21.912
TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
When an ABBV analyst reiterates coverage on stocks, we will let you know. Please make sure you subscribe to our email newsletter to get timely alerts. Join thousands of other investors, you can always unsubscribe.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to ABBV, you should consider joining TipRanks.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================